Eastwood Bio-Medical Canada Inc.

EBM

CA27783W1059

Pharmaceuticals

Market Closed - Toronto S.E. Other stock markets 10:45:16 23/05/2024 pm IST			5-day change	1st Jan Change
0.6 ^CAD	+9.09%		+9.09%	+9.09%

02/04	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
29/02	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI

Eastwood Bio-Medical Canada Inc. Partners with Ruiyan

January 22, 2020 at 11:18 pm IST

Eastwood Bio-Medical Canada Inc. announced it has partnered with Ruiyan. The two companies plan to work together to expand their respective presences in the Chinese, Korean, and North American markets.

Latest news about Eastwood Bio-Medical Canada Inc.

Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	02/04	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	29/02	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	30/23/30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	30/23/30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	01/23/01	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	28/23/28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	28/23/28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	29/22/29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	30/22/30	CI
Eastwood Bio-Medical Canada Inc.(TSXV:EBM) dropped from S&P/TSX Venture Composite Index	18/22/18	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	01/22/01	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2021	01/22/01	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2021	29/21/29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2021	30/21/30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2020	02/21/02	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	01/21/01	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2020	30/20/30	CI
Eastwood Bio-Medical Canada Inc. Appoints Youngsoo Kim as the New Chief Executive Officer	04/20/04	CI
Eastwood Bio-Medical Canada Inc. Announces Executive Change	04/20/04	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2020	30/20/30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2020	31/20/31	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2019	27/20/27	CI
Eastwood Bio-Medical Canada Inc. Partners with Ruiyan	22/20/22	CI
Eastwood Bio-Medical Canada Inc. Introduces New Products	08/19/08	CI

Chart Eastwood Bio-Medical Canada Inc.

Duration

Period

More charts

Company Profile

Eastwood Bio-Medical Canada Inc. is engaged in marketing and distributing natural health products in North America. It is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief.

Sector

Pharmaceuticals

Calendar

27/06/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
EASTWOOD BIO-MEDICAL CANADA INC.	+9.09%	3.03Cr
DONG-E-E-JIAO CO.,LTD.	+37.65%	603.67Cr
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-19.68%	427.46Cr
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+4.49%	327.6Cr
TASLY PHARMACEUTICAL GROUP CO., LTD	-15.69%	296.01Cr
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-5.64%	242.78Cr
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+44.89%	193.03Cr
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-12.71%	159.24Cr
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-4.27%	157.61Cr
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-14.86%	149.75Cr